CDSCO Revised Schedule-M Compliance Dashboard
Revised Schedule-M is binding on every pharmaceutical manufacturing unit in India since 1 January 2026. This dashboard tracks enforcement developments, notifications, and inspection activity — curated and verified by a QA & regulatory affairs professional with 23+ years in the industry.
Latest Revised Schedule-M developments.
Every notification, directive, and enforcement milestone — newest first. Filter by source or search the log.
How ready is your unit? Check in 2 minutes.
Answer honestly across the twelve areas inspectors focus on. Your score stays on your device — nothing is submitted unless you choose to share it.
Applicability and deadline status.
Official portals and practical tools.
CDSCO Official Website
Notifications, circulars, and the authoritative text of Revised Schedule-M under the Drugs & Cosmetics Rules.
cdsco.gov.in →ONDLS Portal
Online National Drugs Licensing System — licence records and the channel used for compliance submissions.
ondls.gov.in →Gap Assessment & Compliance Consultation
Facility-specific Revised Schedule-M gap analysis and upgrade roadmap, led by 23+ years of QA/QC/DRA experience.
laafon.com →Plant Setup Cost Calculator
Estimate Schedule-M compliant plant setup costs — premises, HVAC, machinery — before you commit capital.
Interactive tool →Compliant Plants for Sale & Rent
Buying an already-compliant unit can be faster than upgrading — browse verified listings including Revised Schedule-M ready facilities.
Verified listings →SOP Library
Standard operating procedure references for documentation systems that inspectors expect to see in place.
Free resource →Revised Schedule-M, answered.
Is there any further extension to the Revised Schedule-M deadline?
No. The final MSME window closed on 31 December 2025, and the DCGI has publicly confirmed — including at the 74th Indian Pharmaceutical Congress — that no further extensions will be granted. Since 1 January 2026, Revised Schedule-M applies to every pharmaceutical manufacturing unit in India, and state drug controllers are conducting inspections with monthly compliance reporting to CDSCO.
What happens to units found non-compliant during inspection?
Action under the Drugs and Cosmetics Act, up to and including suspension or cancellation of the manufacturing licence. The DCGI’s 7 November 2025 directive instructed states to take strict action against non-complying units, and the monthly reporting mandate means uninspected units cannot simply stay off the radar.
What are the biggest technical upgrades Revised Schedule-M requires?
The heaviest investments are typically premises and HVAC qualification, water system qualification (purified water / WFI), a documented Pharmaceutical Quality System with quality risk management and product quality reviews, equipment and computerised system validation (IQ/OQ/PQ, CSV), data integrity controls under ALCOA+ principles, and stability study infrastructure. Personnel qualification and GPT-competency training requirements also tightened significantly.
My unit missed the deadline. What should I do first?
Commission a documented gap assessment immediately — it is both the practical first step and the strongest evidence of good faith if an inspector arrives before upgrades finish. Prioritize the gaps that halt manufacturing (premises, water, HVAC) over documentation refinements, and prepare a costed, time-bound upgrade plan. Continuing to manufacture with no assessment and no plan is the highest-risk position a unit can be in right now.
Is buying a compliant plant faster than upgrading my own?
Sometimes, yes. Where an existing facility needs structural civil work, a Revised Schedule-M compliant unit purchased or rented can reach production faster than a 12–18 month upgrade. The right answer depends on your dosage forms, capital position, and the specific gaps — which is exactly what a gap assessment quantifies.
Does Revised Schedule-M align India with WHO and PIC/S GMP?
That is its core purpose — harmonizing Indian GMP with WHO and PIC/S benchmarks so Indian units face fewer duplicative foreign inspections and gain smoother access to regulated export markets. For exporters, compliance is not just a licence issue; it is market access.
Close your Schedule-M gaps before an inspector finds them.
Facility-specific gap assessment, upgrade roadmap, and inspection readiness — from 23+ years inside pharmaceutical QA and regulatory affairs.
DISCLAIMER: This dashboard is curated for general guidance and is updated as developments occur; it does not constitute legal or regulatory advice. Figures such as filing percentages and unit counts are industry estimates reported at the time of each update. Always verify current requirements against official CDSCO / MoHFW notifications before making compliance decisions.